Monte Rosa Therapeutics (GLUE) director granted 25,800 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Monte Rosa Therapeutics director Eric A. Hughes received a grant of stock options covering 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. This is a compensation-related equity award, not an open-market purchase.

All 25,800 options will vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Hughes holds 25,800 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hughes Eric A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,800	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 25,800 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 25,800 options Exercise price: $17.10 per share Underlying shares: 25,800 shares +3 more

6 metrics

Option grant size 25,800 options Stock Option (Right to Buy) granted to director Eric A. Hughes

Exercise price $17.10 per share Exercise price for common stock underlying the option grant

Underlying shares 25,800 shares Common Stock underlying the granted stock options

Expiration date June 11, 2036 Option expiration date for the 25,800 granted options

Vesting date trigger June 11, 2027 or next annual meeting Earlier of the two dates when options vest, subject to continued service

Post-grant derivative holdings 25,800 options Total stock options held directly after the reported grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, underlying security, +2 more

6 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "17.1000" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-11T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Stock""

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting"

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hughes Eric A

(Last)

(First)

(Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON

MASSACHUSETTS

02118

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$17.1	06/11/2026		A		25,800		⁽¹⁾	06/11/2036	Common Stock	25,800	$0	25,800	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Markus Warmuth, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Monte Rosa Therapeutics (GLUE) report for Eric A. Hughes?

Monte Rosa Therapeutics reported a grant of stock options to director Eric A. Hughes covering 25,800 shares of common stock at a $17.10 exercise price, expiring June 11, 2036, as part of his equity-based compensation.

How many Monte Rosa Therapeutics (GLUE) options were granted to Eric A. Hughes and at what price?

Eric A. Hughes received 25,800 stock options for Monte Rosa Therapeutics common stock with an exercise price of $17.10 per share, providing the right to buy the same number of underlying shares if the options vest and are exercised.

When do Eric A. Hughes’s Monte Rosa Therapeutics (GLUE) stock options vest?

The 25,800 stock options granted to Eric A. Hughes vest in full on the earlier of June 11, 2027 or Monte Rosa Therapeutics’ next annual stockholder meeting, provided he continues serving the company through that vesting date.

Are Eric A. Hughes’s Monte Rosa Therapeutics (GLUE) option grants open-market purchases?

No. The Form 4 shows a compensation-related grant of stock options to Eric A. Hughes, coded as an award acquisition. These are derivative securities with a $17.10 exercise price, not shares bought on the open market for cash.

What is Eric A. Hughes’s derivative position in Monte Rosa Therapeutics (GLUE) after this grant?

After the reported transaction, Eric A. Hughes directly holds stock options covering 25,800 shares of Monte Rosa Therapeutics common stock. These options vest in the future and expire on June 11, 2036 if not exercised after vesting.